Answers are grounded in this paper and cite their sources.
Demonstrates effective co-delivery of drugs in triple-negative breast cancer, suggesting a novel therapeutic approach.
A common strategy in cancer therapy involves using a nanoscale carrier to simultaneously deliver phototherapeutic agents and chemotherapeutic drugs. However, traditional delivery carriers are toxic and immunogenic, and their preparation involves complex procedures, limiting their widespread application. Exosomes (Exo) are spherical, lipid bilayer vesicles that have a diameter of 50-150 nm. They are naturally secreted by various cells and can cross multiple biological barriers, making them attractive alternatives. Dunaliella salina-derived exosome-like nanovesicles (DENV) represent promising drug nanocarriers due to their excellent biocompatibility, low immunogenicity, low cost, and large-scale, rapid production. However, the role of DENV in triple-negative breast cancer, which has the highest rates of metastasis and recurrence, is unknown. In this study, DENVs were prepared by ultracentrifugation. Indocyanine green (ICG) and 5-fluorouracil (5-FU) were co-loaded into DENV (DENV-ICG/5-FU) via electroporation. DENV-ICG/5-FU exhibited good photothermal performance and stability. At a pH of 5.0 and exposure to 808 nm near-infrared (NIR) light at 1 W/cm2 for 5 minutes, the cumulative release of 5-FU from the DENV-ICG/5-FU was 86.45%. In addition, DENV-ICG/5-FU was internalized into 4T1 breast cancer cells. Under NIR irradiation, it inhibited proliferation and migration and induced apoptosis of 4T1 cells. Results from flow cytometry and DCFH-DA analyses indicated that NIR irradiation significantly increased both the proportion of cells in the G1 phase and the generation of ROS. Mechanism studies showed that under NIR irradiation, DENV-ICG/5-FU enhanced the expression of the pro-apoptotic protein Bax. In summary, these findings suggest that DENV could be ideal vehicles to co-deliver phototherapeutic agents and chemotherapeutic drugs for synergistic tumor treatment.
No takes yet. Share an insight, caveat, or question.
An et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: